Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin for salivary gland preservation during neck radiotherapy
IRCT20180225038862N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of botulinum toxin type A in head and neck cancer (HNC) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Xerostomia. Started Oct 2017; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on IRCT20180225038862N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180225038862N1.